Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Industry Needs Pricing System That Rewards Innovation: JPMA President Dr Aoki
January 14, 2008
- GMP for Investigational Drugs to Be Amended
January 14, 2008
- JAPhMed to Certify Pharmaceutical Medicine Specialists
January 14, 2008
- REGULATORY NEWS IN BRIEF
January 14, 2008
- Complete Lifting of Ban on Kongyo Shinryo Not Recommended by Council
January 14, 2008
- Non-Tamiflu Users Show Higher Incidence of Abnormal Behavior: Study Team Report
January 14, 2008
- ON THE MOVE／J&J Appoints D. W. Powell President
January 14, 2008
- Abnormal Behavior Reported in 38% of Patients Not Taking Tamiflu
January 14, 2008
- R&D NEWS IN BRIEF
January 14, 2008
- Nexavar, Licomodulin, Zevalin to Be Officially Approved Soon
January 14, 2008
- Korosho's General Account Budget to Total \22,117.9 Bil.
January 14, 2008
- Korosho to Promote the Use of Generics by Welfare Recipients
January 14, 2008
- Rules to Be Revised to Oblige Pharmacists to Dispense Generics: Mr Urushibata
January 14, 2008
- Only 16% of Consumers Ask Doctors for Generics Despite High Awareness Rate
January 14, 2008
- Isoconazole, Emedastine to Be Switched to OTC
January 7, 2008
- AstraZeneca to Revise Invoice Prices as Market Conditions Change
January 7, 2008
- R&D NEWS IN BRIEF
January 7, 2008
- aRigen Licenses ARB-CF0223 to Axentis
January 7, 2008
- Takeda Initiates PIII Program for Lu AA21004
January 7, 2008
- Otsuka Acquires IV Busulfex from PDL BioPharma
January 7, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…